Novartis news - the latest biotech news from Labiotech.eu

Home Novartis Page 6

Latest Posts

News and Trends 30 Sep 2016

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company’s CFO, who explained its advantageous position against big pharma. GeNeuro raised €33M in its Euronext IPO in April and is currently competing against giants like Novartis and Biogen. Despite 2016’s dubious honor as “the worst year for IPO in 20 years”, this Switzerland-based company has managed to go […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

shutterstock 117198280 1 e1474987771873

News and Trends 29 Sep 2016

Debunking the Immuno-Oncology Hype: is it as good as it sounds?

CAR-T therapies have gained plenty of attention lately by promising to end cancer with a one-off treatment. But all that glitters is not gold; experts remind us it is important to be critical about the immuno-oncology hype. Immuno-oncology has become all the rage lately, and the hype has led to some major investments, acquisitions, deals and partnerships. It seems […]

September 29, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Sep 2016

UPDATE: Novartis is Favoured to Win the Race for a New MS Drug

Novartis is poised to kick off the next generation of multiple sclerosis treatments after siponimod performs well in Phase III. The company’s primary competitor had been Biogen, but its drug’s failure in Phase II leaves siponimod the last man standing. Novartis reports that its multiple sclerosis (MS) drug, siponimod, has reached its primary endpoint in Phase III […]

September 20, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 27 Apr 2016

‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease

MorphoSys confirms that its antibody (bimagrumab) failed to meet the primary endpoint of a phase IIb/III trial for a muscle disease (sIBM), conducted by Novartis. Sad news for Novartis and MorphoSys. The two companies are developing bimagrumab for muscle diseases, as part of their ongoing collaboration, which has already resulted in 11 programmes. Bimagrumab was initially […]

April 27, 2016 - 2 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT